Comparison of Fasting Human Pancreatic Polypeptide Levels Among Patients With Pancreatic Ductal Adenocarcinoma, Chronic Pancreatitis, and Type 2 Diabetes Mellitus.
Comparison of Fasting Human Pancreatic Polypeptide Levels Among Patients With Pancreatic Ductal Adenocarcinoma, Chronic Pancreatitis, and Type 2 Diabetes Mellitus.
复制标题
胰管腺癌、慢性胰腺炎和2型糖尿病患者空腹人胰多肽水平的比较。
DOI:
10.1097/mpa.0000000000001077
复制
发表时间:
2018
期刊:
影响因子:
2.9
通讯作者:
Chari,SureshT
中科院分区:
文献类型:
--
作者:
Nagpal,SajanJivSingh;Bamlet,WilliamR;Kudva,YogishC;Chari,SureshT
ObjectivesHuman pancreatic polypeptide (HPP) is a hormone secreted by the ventral pancreas. While postprandial HPP levels have been studied in chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC), there are limited data on fasting HPP in these diseases.MethodsFasting serum HPP was measured in the following groups of patients: CP with diabetes mellitus (DM)(n= 16), CP without DM (n= 34), PDAC with new-onset DM (n= 50), PDAC without DM (n= 49), new-onset type 2 DM (n= 50), and controls without DM (n= 49). Sixty-six had type 3c DM (CP with DM, n= 16; PDAC with new-onset DM, n= 50).ResultsMedian fasting HPP levels (in picograms per milliliter) were similar among all groups. Median (interquartile range) HPP levels in new-onset type 2 DM (n= 50; 288.3 [80.1–1072.1]) were similar to those in type 3c DM (n= 66; 242.3 [64.9–890.9])(P= 0.71). In PDAC (n= 99), HPP values were similar in pancreatic head (n= 75) versus body/tail (n= 24) tumors (245.3 [64.3–1091.3] vs 334.7 [136.1–841.5]; P= 0.95), regardless of DM.Conclusions